News

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

The company is planning to use its mRNA platform to develop the vaccine for malaria, which is the same successful technology it harnessed for its COVID-19 vaccine.

With its latest earnings report showing the financial impact of the vaccine, the Delta variant becoming the dominant strain in the US, and concerns of waning immunity, the company believes there is evidence for an additional booster shot.

A new report based on wearable technology finds it takes an average of 79 days for patients’ resting heart rates to return to normal following COVID-19 infection.

Commonly reported issues included delirium, encephalopathies and psychiatric complications.

Public information campaigns may potentially boost rates of vaccination.

As much as 2% of vaccine recipients have reported anaphylaxis following their first shot.

A recent study of sexually active young women in Africa found that initiation of HIV preexposure prophylaxis (PrEP) was high at 95% and one-fifth showed high adherence at 6 months.

Asymptomatic and symptomatic COVID-19 cases among health care personnel were reduced after vaccination despite surge in infected patients.

The nasal mucosa was seen to be an essential determinant of overall disease trajectory.

The framework could help officials assess the true burden of disease in certain areas.

In a small study, the newly FDA approved antifungal demonstrated “clinical activity” against the emerging pathogen.

Use of remdesivir for COVID-19 was associated with longer hospital stays but was not associated with improved mortality, a recent study of 2344 patients at 123 VA hospitals found.

This approval of the non-live, recombinant sub-unit adjuvanted vaccine, Shingrix, is for the prevention of shingles in adults aged 18 years and older with increased risk of immunodeficiency or immunosuppression.

Modeling showed 1 in 4 infected people pass the infection to a family member.

Pfizer and Moderna will include children aged 5-11 years old in ongoing trials to speak toward risk of rare adverse events observed in other young recipients.

The statement includes over 50 societies and organizations, representing millions of workers.

The company will review the CRL and request a Type A meeting in the coming weeks.

This therapy becomes the first single-dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.

Communities experiencing such health inequity and disparities are more likely to have mistrust in systems that have continuously failed them. Understanding the perspectives of those disproportionately affected is critical to not only address them, but also work to correct and prevent these disparities moving forward.

An emergency department in Canada saw a steep drop in emergency department visits and a spike in the proportion of serious bacterial infections among newborns and young infants during the first year of the pandemic, a new study found.

With millions of Americans affected by sexually transmitted infections (STI) an emphasis on prevention and control strategies was included in the recommendations.

Not much is known about the relationship between the expression and activity of SPM pathways and COVID-19 disease severity.

The clusters were identified in Washington, DC, and the Dallas area.

The lineage C.37, (Lambda variant), was recently classified as a variant of interest by the World Health Organization (WHO) based on its high circulation rates in South America, and has showed "the ability to escape from neutralizing antibodies elicited by CoronaVac."

Due to limited familiarity with providing antiretroviral medication, many participants were hesitant to initiate PrEP.

Associations found in people under the age of 45 were weaker in patients over that age.

Patients with a history of malnutrition had higher odds of developing severe disease.